Day One Biopharmaceuticals (NASDAQ:DAWN) Upgraded at TD Cowen

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) was upgraded by analysts at TD Cowen to a "strong-buy" rating in a report issued on Monday, Zacks.com reports.

Several other research analysts have also commented on the stock. Needham & Company LLC restated a "buy" rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. Bank of America raised Day One Biopharmaceuticals from an "underperform" rating to a "buy" rating and increased their price objective for the company from $11.00 to $24.00 in a report on Thursday, August 1st. HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. JPMorgan Chase & Co. dropped their price target on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 6th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Monday, July 8th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $35.71.

Day One Biopharmaceuticals Stock Up 2.3 %

Shares of Day One Biopharmaceuticals stock traded up $0.34 during midday trading on Monday, hitting $15.15. The company's stock had a trading volume of 1,683,220 shares, compared to its average volume of 942,660. Day One Biopharmaceuticals has a 1-year low of $10.90 and a 1-year high of $18.07. The firm has a market capitalization of $1.53 billion, a P/E ratio of -14.73 and a beta of -1.51. The stock has a 50-day simple moving average of $14.20 and a 200-day simple moving average of $14.38.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.58. The firm had revenue of $93.76 million for the quarter, compared to analyst estimates of $15.05 million. During the same period in the previous year, the business posted ($0.54) EPS. As a group, sell-side analysts predict that Day One Biopharmaceuticals will post -1.22 earnings per share for the current year.

Insider Activity

In related news, insider Samuel C. Blackman sold 30,000 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total transaction of $426,600.00. Following the completion of the transaction, the insider now directly owns 1,097,535 shares of the company's stock, valued at $15,606,947.70. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, insider Samuel C. Blackman sold 2,232 shares of the business's stock in a transaction on Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $31,248.00. Following the completion of the sale, the insider now owns 1,127,535 shares in the company, valued at $15,785,490. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Samuel C. Blackman sold 30,000 shares of the firm's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total value of $426,600.00. Following the completion of the transaction, the insider now owns 1,097,535 shares in the company, valued at approximately $15,606,947.70. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 49,248 shares of company stock worth $697,082. Company insiders own 8.40% of the company's stock.

Institutional Trading of Day One Biopharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in DAWN. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Day One Biopharmaceuticals by 38.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company's stock worth $51,000 after buying an additional 1,002 shares during the period. ProShare Advisors LLC grew its position in shares of Day One Biopharmaceuticals by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 17,379 shares of the company's stock worth $287,000 after buying an additional 1,447 shares during the period. SteelPeak Wealth LLC raised its holdings in Day One Biopharmaceuticals by 9.8% during the 3rd quarter. SteelPeak Wealth LLC now owns 17,400 shares of the company's stock worth $242,000 after buying an additional 1,550 shares during the period. Handelsbanken Fonder AB lifted its stake in Day One Biopharmaceuticals by 16.9% in the third quarter. Handelsbanken Fonder AB now owns 27,000 shares of the company's stock valued at $376,000 after buying an additional 3,900 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Day One Biopharmaceuticals by 8.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 64,359 shares of the company's stock valued at $887,000 after buying an additional 5,070 shares during the period. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.